Marco Bertolotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/913237/publications.pdf

Version: 2024-02-01

103 papers

3,170 citations

28 h-index 54 g-index

108 all docs

108 docs citations

108 times ranked 4706 citing authors

#	Article	IF	CITATIONS
1	Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 830-840.	1.4	467
2	Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology, 1997, 113, 1264-1269.	0.6	325
3	Nonalcoholic fatty liver disease and aging: Epidemiology to management. World Journal of Gastroenterology, 2014, 20, 14185.	1.4	227
4	Endocrine and liver interaction: the role of endocrine pathways in NASH. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 236-247.	8.2	127
5	Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates. Digestive Diseases and Sciences, 2003, 48, 2173-2181.	1.1	123
6	Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Disease, 2002, 34, 204-211.	0.4	106
7	Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials. International Journal of Molecular Sciences, 2019, 20, 4256.	1.8	106
8	Effects of acute changes of bile acid pool composition on biliary lipid secretion Journal of Clinical Investigation, 1984, 74, 614-624.	3.9	99
9	Gallstone disease in non-alcoholic fatty liver: Prevalence and associated factors. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1176-1184.	1.4	80
10	Genetic polymorphisms in non-alcoholic fatty liver disease: Interleukin-6â^174G/C polymorphism is associated with non-alcoholic steatohepatitis. Digestive and Liver Disease, 2009, 41, 823-828.	0.4	76
11	Serum time course of naltrexone and $6\hat{l}^2$ -naltrexol levels during long term treatment in drug addicts. Drug and Alcohol Dependence, 1998, 52, 211-220.	1.6	68
12	Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?. Internal and Emergency Medicine, 2013, 8, 297-305.	1.0	66
13	Regulation of bile acid synthesis in humans: Effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7α-hydroxylation ratesin vivo. Hepatology, 1991, 14, 830-837.	3.6	61
14	Influence of age and sex on serum concentrations of total dimeric activin A. European Journal of Endocrinology, 1998, 139, 487-492.	1.9	54
15	Fatty liver, carotid disease and gallstones: A study of age-related associations. World Journal of Gastroenterology, 2006, 12, 5826.	1.4	53
16	Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. European Journal of Clinical Investigation, 2007, 37, 501-508.	1.7	52
17	Telomere length elongation after weight loss intervention in obese adults. Molecular Genetics and Metabolism, 2016, 118, 138-142.	0.5	47
18	Prevalence rates of gallstone disease in Italy. European Journal of Epidemiology, 1994, 10, 143-150.	2.5	45

#	Article	IF	Citations
19	Multidisciplinary Approach to the Treatment of Metabolic and Morphologic Alterations of HIV-Related Lipodystrophy. HIV Clinical Trials, 2006, 7, 97-106.	2.0	45
20	ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population. Digestive and Liver Disease, 2013, 45, 226-232.	0.4	45
21	Risk of birth defects associated with maternal pregestational diabetes. European Journal of Epidemiology, 2014, 29, 411-418.	2.5	44
22	Effect of liver cirrhosis on the systemic availability of naltrexone in humans. Journal of Hepatology, 1997, 27, 505-511.	1.8	40
23	Effects of Different Phenotypes of Hyperlipoproteinemia and of Treatment With Fibric Acid Derivatives on the Rates of Cholesterol 7α-Hydroxylation in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1064-1069.	1.1	39
24	Nutraceutical approach for the management of cardiovascular risk $\hat{a} \in \hat{a}$ a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. Nutrition Journal, 2019, 18, 13.	1.5	37
25	Effect of ursocholic acid on bile lipid secretion and composition. Gastroenterology, 1986, 90, 865-874.	0.6	34
26	Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. European Journal of Clinical Investigation, 2006, 36, 170-175.	1.7	33
27	Physical exercise for late life depression: effects on cognition and disability. International Psychogeriatrics, 2017, 29, 1105-1112.	0.6	33
28	Instrumental assessment of balance and gait in depression: A systematic review. Psychiatry Research, 2020, 284, 112687.	1.7	33
29	Suppression of bile acid synthesis, but not of hepatic cholesterol 7α-hydroxylase expression, by obstructive cholestasis in humans. Hepatology, 2001, 34, 234-242.	3.6	31
30	Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. Hepatology, 1994, 19, 882-888.	3.6	30
31	Review article: effect of bile salt pool composition on hepatic and biliary functions. Alimentary Pharmacology and Therapeutics, 2000, 14, 14-18.	1.9	30
32	Cholecystokinin Increases Bile Acid Synthesis with Total Parenteral Nutrition but Does Not Prevent Stone Formation. Journal of Surgical Research, 1997, 67, 84-89.	0.8	26
33	Meal-induced blood pressure variation and cardiovascular mortality in ambulatory hypertensive elderly patients. Journal of Hypertension, 2012, 30, 2125-2132.	0.3	24
34	Variable phenotypic expression of homozygous familial hypobetalipoproteinaemia due to novel <i>APOB </i> journments of the control of the cont	1.0	22
35	Analgesic Drug Taking: Beliefs and Behavior Among Headache Patients. Headache, 1997, 37, 88-94.	1.8	21
36	Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans. Hepatology, 1997, 25, 1306-1314.	3.6	21

#	Article	IF	CITATIONS
37	Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population. Clinical Interventions in Aging, 2014, 9, 425.	1.3	21
38	Regulation of hepatic cholesterol metabolism in the rat in vivo: Effect of a synthetic fat-free diet on sterol synthesis and low-density lipoprotein transport. Lipids and Lipid Metabolism, 1995, 1255, 293-300.	2.6	20
39	Protective effect of estrogens on bile acid induced cell damage in HEPG2 cells. Journal of Hepatology, 2003, 38, 188-189.	1.8	18
40	Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2012, 44, 1018-1026.	0.4	18
41	Nonalcoholic Fatty Liver Disease Induced by Leuprorelin Acetate. Journal of Clinical Gastroenterology, 2008, 42, 107-110.	1.1	16
42	Risk for cardiovascular events in an Italian population of patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 885-892.	1.1	16
43	Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: A possible compensatory mechanism. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 823-830.	1.1	16
44	Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1580, 31-39.	1.2	15
45	Review article: hyperlipidaemia and cardiovascular risk. Alimentary Pharmacology and Therapeutics, 2005, 22, 28-30.	1.9	14
46	Bleeding jejunal varices and portal thrombosis in a splenectomized patient with hereditary spherocytosis. Digestive Diseases and Sciences, 2000, 45, 373-377.	1.1	13
47	Nuclear Receptors as Potential Molecular Targets in Cholesterol Accumulation Conditions: Insights from Evidence on Hepatic Cholesterol Degradation and Gallstone Disease in Humans. Current Medicinal Chemistry, 2008, 15, 2271-2284.	1.2	13
48	Disposition of Naproxen After Oral Administration During and Between Migraine Attacks. Headache, 1993, 33, 191-194.	1.8	12
49	Acute Abdomen Associated with Schistosomiasis of the Appendix. Digestive Diseases and Sciences, 2006, 51, 215-217.	1.1	12
50	Correlation between plasma levels of $7\hat{l}_{\pm}$ -hydroxy-4-cholesten-3-one and cholesterol $7\hat{l}_{\pm}$ -hydroxylation rates in vivo in hyperlipidemic patients. Steroids, 2008, 73, 1197-1202.	0.8	12
51	Lipoprotein Glomerulopathy Associated with a Mutation in Apolipoprotein E. Clinical Medicine Insights: Case Reports, 2013, 6, CCRep.S12209.	0.3	12
52	Statins and HCV: A complex issue. Hepatology, 2007, 45, 257-257.	3.6	11
53	Social engagement in late life may attenuate the burden of depressive symptoms due to financial strain in childhood. Journal of Affective Disorders, 2020, 263, 336-343.	2.0	11
54	Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?. Internal and Emergency Medicine, 2009, 4, 71-73.	1.0	10

#	Article	IF	Citations
55	Novel Genetic Mutation in Apolipoprotein E2 Homozygosis and Its Implication in Organ Donation: A Case Report. Transplantation Proceedings, 2010, 42, 1349-1351.	0.3	10
56	Plasma glutathione level in paracetamol daily abuser patients. Changes in plasma cysteine and thiol groups after reduced glutathione administration. Toxicology Letters, 1992, 64-65, 757-761.	0.4	9
57	Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology, 2003, 38, 939-946.	3.6	9
58	Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina) Tj ETQq0	0 0. æBT /	Overlock 10
59	Pharmacokinetics of Tiaprofenic Acid After Oral Administration in Fasting Patients During and Between Migraine Attacks. Headache, 1990, 30, 672-675.	1.8	7
60	The Use of Stable and Radioactive Sterol Tracers as a Tool to Investigate Cholesterol Degradation to Bile Acids in Humans in Vivo. Molecules, 2012, 17, 1939-1968.	1.7	7
61	Use of Lipid-Lowering Drugs and Associated Outcomes According to Health State Profiles in Hospitalized Older Patients. Clinical Interventions in Aging, 2021, Volume 16, 1251-1264.	1.3	7
62	Ursodeoxycholic Acid Improves Liver Tests in Chronic Hepatitis. Clinical Drug Investigation, 1999, 17, 425-434.	1.1	6
63	17beta-estradiol prevents cytotoxicity from hydrophobic bile acids in HepG2 and WRL-68 cell cultures. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 894-901.	1.4	6
64	Changes in bile acid synthesis in gallstone disease: Cause, consequence, or neither?. Hepatology, 2007, 46, 1664-1664.	3 . 6	6
65	Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma. Journal of Clinical Virology, 2015, 69, 74-77.	1.6	6
66	Management of high cholesterol levels in older people. Geriatrics and Gerontology International, 2019, 19, 375-383.	0.7	6
67	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red) Tj ETQc	1 1.0 .784	-31 4 rgBT /0
68			

#	Article	IF	CITATIONS
73	Advances in the Comprehension of the Pathophysiology of Bile Secretion. Digestive Diseases, 1991, 9, 142-155.	0.8	2
74	Effect of diabetic autonomic neuropathy on gall bladder kinetics in insulin-dependent diabetic patients. European Journal of Gastroenterology and Hepatology, 1994, 6, 765-772.	0.8	2
7 5	Olanzapine metabolic side effects: a weight gain issue?. Internal and Emergency Medicine, 2008, 3, 237-240.	1.0	2
76	Predictive Factors of Lack of Response to Antiviral Therapy Among in Patients With Recurrent Hepatitis C After Liver Transplantation. Transplantation Proceedings, 2010, 42, 1223-1225.	0.3	2
77	Bile acids and nonalcoholic fatty liver disease: An intriguing relationship. Hepatology, 2016, 63, 1739-1740.	3.6	2
78	Reduced multidrug resistance-associated protein 2 in ticlopidine-induced cholestatic liver injury. Digestive and Liver Disease, 2020, 52, 236-238.	0.4	2
79	Serum naltrexone and 6-beta-naltrexol concentrations in detoxified heroin addicts during long term naltrexone treatment. Pharmacological Research, 1992, 25, 196-197.	3.1	1
80	575 Non alcoholic fatty liver disease (NAFLD): Is female sex safer?. Journal of Hepatology, 2004, 40, 168.	1.8	1
81	[300] HEPATIC EXPRESSION OF NUCLEAR RECEPTORS AND BILIARY TRANSPORTERS IN HUMAN CHOLESTEROL GALLSTONE DISEASE. Journal of Hepatology, 2007, 46, S119.	1.8	1
82	Effect of taurohyodeoxycholic acid on biliary lipid secretion in man. Hepatology, 1993, 18, A308.	3.6	1
83	Interactions between Chronic Headache and Analgesic Drugs Overuse: Clinical and Toxicological Aspects Cephalalgia, 1991, 11, 212-213.	1.8	0
84	Pharmacokinetics of naproben after oral administration during and out of migraine attacks. Pharmacological Research, 1992, 25, 208-209.	3.1	0
85	Pharmacokinetic of reduced glutathione in man: Effect on plasma cysteine and thiol compounds. Pharmacological Research, 1992, 25, 218-219.	3.1	0
86	Extent of bile acid-induced hepatic damage dictates activin a secretion in HepG2 cells. Journal of Hepatology, 2000, 32, 77.	1.8	0
87	Suppression of in vivo bile acid synthesis, but not of in vitro cholesterol 7α-hydroxylase expression, by biliary obstruction in humans. Journal of Hepatology, 2000, 32, 121.	1.8	0
88	Prevalence and determinants of gallstone disease in NAFLD. Journal of Hepatology, 2003, 38, 186-187.	1.8	0
89	576 Non alcoholic fatty liver disease (NAFLD) and insulin resistance: Does PC-1K121Q play a role?. Journal of Hepatology, 2004, 40, 169.	1.8	0
90	W11-P-003 Genetics of NAFLD: Role of cytokine polymorphisms. Atherosclerosis Supplements, 2005, 6, 57.	1.2	0

#	Article	IF	CITATIONS
91	W15-P-001 Role of nuclear receptors in the molecular regulation of cholesterol homeostasis in cultured human hepatocytes. Atherosclerosis Supplements, 2005, 6, 96-97.	1.2	O
92	310 Hepatic expression of PPAR- \hat{l}^3 coactivator 1 (PGC-1) is reduced in human cholelithiasis. Journal of Hepatology, 2006, 44, S120.	1.8	0
93	710 Different free fatty acids (FFA) affect steatosis extent and hepatocyte apoptosis. Evidence from an in vitro study. Journal of Hepatology, 2006, 44, S261.	1.8	0
94	Tu-P8:323 Hepatic nuclear receptors in human cholelithiasis: A link with insulin resistance?. Atherosclerosis Supplements, 2006, 7, 256.	1.2	0
95	We-P12:289 Structure and concentration of different fatty acids (FFAS) affect steatosis extent and apoptosis in hepatocyte coltures. Atherosclerosis Supplements, 2006, 7, 410.	1.2	0
96	PO5-118 INTERLEUKIN-6-174G/C POLYMORPHISM IS ASSOCIATED WITH INSULIN RESISTANCE IN NAFLD. A CLUE TO DISEASE SUSCEPTIBILITY?. Atherosclerosis Supplements, 2007, 8, 46.	1.2	0
97	Reply:. Hepatology, 2008, 47, 1797-1798.	3.6	O
98	Liver X receptors and copper metabolism: New frontiers for the oxysterol receptors. Hepatology, 2016, 64, 1371-1371.	3.6	0
99	Case of an old man with aortic dissection type A and enlarging meningioma. Aging Clinical and Experimental Research, 2017, 29, 1071-1072.	1.4	O
100	The relationship between age and fat infiltration in liver and muscle. Journal of Hepatology, 2017, 67, 881-883.	1.8	0
101	Determinants of Biliary Cholesterol Secretion. , 1987, , 49-58.		O
102	Regulation of bile acid synthesis in humans: Effects of hyperlipidemia and gemfibrozil treatment on the rates of cholesterol 7\$alpha;-hydroxylation ?in vivo?. Hepatology, 1993, 18, A304.	3.6	0
103	Bioavailability of naltrexone and 6\$beta;-naltrexol after oral naltrexone administration in patients with liver cirrhosis. Hepatology, 1993, 18, A312.	3.6	0